Program Status
Active, not recruitingPhase
Phase 1Prior Immunotherapy Allowed
YesCRC-directed Trial
YesTags
MSI-H/ MMRd, MSS/ MMRpComments
For NED (no evidence of disease) patients, who had KRAS/NRAS mutated, G12D or G12R, solid tumor, including colorectal cancer.
Helpful Links
https://www.nature.com/articles/s41591-023-02760-3| Location | Location Status |
|---|---|
| United States | |
|
City of Hope Duarte, California 91010 |
Active, not recruiting |
|
University of California Los Angeles Los Angeles, California 90095 |
Active, not recruiting |
|
University of Colorado Aurora, Colorado 80045 |
Active, not recruiting |
|
University of Iowa Iowa City, Iowa 52242 |
Active, not recruiting |
|
Massachusetts General Hospital Boston, Massachusetts 02114 |
Active, not recruiting |
|
Washington University School of Medicine Saint Louis, Missouri 63110 |
Active, not recruiting |
|
Northwell Health Lake Success, New York 11042 |
Active, not recruiting |
|
Memorial Sloan Kettering Cancer Center New York, New York 10065 |
Active, not recruiting |
|
Tennessee Oncology - Centennial Clinic Nashville, Tennessee 37203 |
Active, not recruiting |
|
The University of Texas MD Anderson Cancer Center Houston, Texas 77030 |
Active, not recruiting |
Inclusion Criteria
Inclusion Criteria:
* KRAS/NRAS mutated (G12D or G12R) solid tumor
* Positive for circulating tumor DNA (ctDNA) and/or elevated serum tumor biomarker despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable
* Screening CT is negative for recurrent disease
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria
Exclusion Criteria:
* Presence of tumor mutations where specific therapy is approved, and the patient is able to receive the approved therapy
* Known brain metastases
* Use of immunosuppressive drugs
